Found: 14
Select item for more details and to access through your institution.
Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 2, p. 411, doi. 10.3390/cells10020411
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e15, doi. 10.1016/j.clml.2019.09.022
- By:
- Publication type:
- Article
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S253, doi. 10.1016/j.clml.2018.07.155
- By:
- Publication type:
- Article
Dysregulation of the Receptor Activator of NF-κB Ligand and Osteoprotegerin Production Influence the Apoptosis of Multiple Myeloma Patients’ Bone Marrow Stromal Cells Co-Cultured with Myeloma Cells.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2010, v. 58, n. 2, p. 153, doi. 10.1007/s00005-010-0070-5
- By:
- Publication type:
- Article
Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2006, v. 54, n. 4, p. 289, doi. 10.1007/s00005-006-0033-z
- By:
- Publication type:
- Article
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
- By:
- Publication type:
- Article
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients.
- Published in:
- Folia Histochemica et Cytobiologica, 2011, v. 49, n. 2, p. 267, doi. 10.5603/FHC.2011.0037
- By:
- Publication type:
- Article
Treatment of multiple myeloma patients with autologous stem cell transplantation - a fresh analysis.
- Published in:
- Folia Histochemica et Cytobiologica, 2011, v. 49, n. 2, p. 248, doi. 10.5603/FHC.2011.0034
- By:
- Publication type:
- Article
Real-life experience with bortezomib-based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study.
- Published in:
- Polish Archives of Internal Medicine, 2017, v. 127, n. 11, p. 765, doi. 10.20452/pamw.4099
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 896, doi. 10.1111/bjh.14787
- By:
- Publication type:
- Article
Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer
- Published in:
- Cell Biology International, 2005, v. 29, n. 7, p. 497, doi. 10.1016/j.cellbi.2005.01.007
- By:
- Publication type:
- Article
Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations.
- Published in:
- Acta Haematologica Polonica, 2021, v. 52, n. 6, p. 528, doi. 10.5603/AHP.a2021.0097
- By:
- Publication type:
- Article
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
- Published in:
- Hematological Oncology, 2013, v. 31, n. 1, p. 41, doi. 10.1002/hon.2018
- By:
- Publication type:
- Article
A Stepwise Screening Protocol for Multiple Myeloma.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 4, p. 1345, doi. 10.3390/jcm12041345
- By:
- Publication type:
- Article